FRI0320 Pregnancy Outcomes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Background Biological agents (“biologics”), such as anti-tumor necrosis factor (TNF) agents and interleukin-6 (IL-6) inhibitors, have been widely used in recent years for the treatment of rheumatoid arthritis (RA) to achieve remission. A concomitant treatment of methotrexate (MTX) with biologics is...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 73; no. Suppl 2; pp. 501 - 502 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.06.2014
|
Online Access | Get full text |
Cover
Loading…
Abstract | Background Biological agents (“biologics”), such as anti-tumor necrosis factor (TNF) agents and interleukin-6 (IL-6) inhibitors, have been widely used in recent years for the treatment of rheumatoid arthritis (RA) to achieve remission. A concomitant treatment of methotrexate (MTX) with biologics is recommended for RA patients refractory to MTX, particularly younger patients who need a high quality of daily life with less joint destruction and physical dysfunction. Although RA is one of the systemic autoimmune diseases that can often occur in women of reproductive age, the evidence of successful treatment of patients who are pregnant or planning for pregnancy is limited due to a lack of prospective case-control studies. Objectives Use of Tocilizumab (TCZ), such as interleukin-6 inhibitors, is recommended for patients who can not use the MTX. A strategy that includes RA treatment, a safe pregnancy and a healthy fetus is clearly needed. Most cases of TCZ prescribed to pregnant RA patients were found to produce satisfactory outcomes, but further information on the association between TCZ and pregnancy is lacking. The aim of this retrospective study is to investigate the details of TCZ use in pregnant RA patients, from planning the pregnancy to actual delivery, and to examine the pregnancy outcomes of RA patients treated before or at conception with TCZ. Methods In 1356 cases of RA patients registered in Nagoya medical center, patients using biologics were 532 cases. Of which, patients treated with TCZ were 111 examples. 7 pregnancies were identified and observed from the 111 patients treated with TCZ Results 7 pregnancy of patients in the TCZ use six cases (one case of preterm low birth weight infants), abortion was 1 cases. They age were from 28 years to 42 years. Five cases was (washout period was from 2 months to 11 months) pregnant after Biologics free. One case was continued TCZ during pregnancy. Medical condition had worsened during pregnancy are three cases, there were four cases of what deterioration was observed after delivery. Table 1 Conclusions TCZ is a pregnancy risk category C drug, according to the US FDA. The category C risk summary states the following: “Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks”. Japanese drug information states that TCZ should be administered to pregnant patients only if the benefits outweigh the risks; therefore, TCZ use in pregnant RA patients is not necessarily prohibited. Still, some review papers have concluded that TCZ should be discontinued three months before conception reported that IL-6 was the one of the causes of preterm premature rupture of membranes (PPROM) and that TCZ inhibited IL-6-mediated matrix metalloproteinase-2 and -9 secretion from human amnion cells. Although their study showed that TCZ might be useful for treating PPROM, the data on TCZ and pregnancy in humans were too limited to make conclusions on safety or suggestions on prescriptions. References Østensen M, et al.Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011; 23: 293-8. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1417 |
---|---|
AbstractList | Background Biological agents (“biologics”), such as anti-tumor necrosis factor (TNF) agents and interleukin-6 (IL-6) inhibitors, have been widely used in recent years for the treatment of rheumatoid arthritis (RA) to achieve remission. A concomitant treatment of methotrexate (MTX) with biologics is recommended for RA patients refractory to MTX, particularly younger patients who need a high quality of daily life with less joint destruction and physical dysfunction. Although RA is one of the systemic autoimmune diseases that can often occur in women of reproductive age, the evidence of successful treatment of patients who are pregnant or planning for pregnancy is limited due to a lack of prospective case-control studies. Objectives Use of Tocilizumab (TCZ), such as interleukin-6 inhibitors, is recommended for patients who can not use the MTX. A strategy that includes RA treatment, a safe pregnancy and a healthy fetus is clearly needed. Most cases of TCZ prescribed to pregnant RA patients were found to produce satisfactory outcomes, but further information on the association between TCZ and pregnancy is lacking. The aim of this retrospective study is to investigate the details of TCZ use in pregnant RA patients, from planning the pregnancy to actual delivery, and to examine the pregnancy outcomes of RA patients treated before or at conception with TCZ. Methods In 1356 cases of RA patients registered in Nagoya medical center, patients using biologics were 532 cases. Of which, patients treated with TCZ were 111 examples. 7 pregnancies were identified and observed from the 111 patients treated with TCZ Results 7 pregnancy of patients in the TCZ use six cases (one case of preterm low birth weight infants), abortion was 1 cases. They age were from 28 years to 42 years. Five cases was (washout period was from 2 months to 11 months) pregnant after Biologics free. One case was continued TCZ during pregnancy. Medical condition had worsened during pregnancy are three cases, there were four cases of what deterioration was observed after delivery. Table 1 Conclusions TCZ is a pregnancy risk category C drug, according to the US FDA. The category C risk summary states the following: “Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks”. Japanese drug information states that TCZ should be administered to pregnant patients only if the benefits outweigh the risks; therefore, TCZ use in pregnant RA patients is not necessarily prohibited. Still, some review papers have concluded that TCZ should be discontinued three months before conception reported that IL-6 was the one of the causes of preterm premature rupture of membranes (PPROM) and that TCZ inhibited IL-6-mediated matrix metalloproteinase-2 and -9 secretion from human amnion cells. Although their study showed that TCZ might be useful for treating PPROM, the data on TCZ and pregnancy in humans were too limited to make conclusions on safety or suggestions on prescriptions. References Østensen M, et al.Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011; 23: 293-8. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1417 Background Biological agents ("biologics"), such as anti-tumor necrosis factor (TNF) agents and interleukin-6 (IL-6) inhibitors, have been widely used in recent years for the treatment of rheumatoid arthritis (RA) to achieve remission. A concomitant treatment of methotrexate (MTX) with biologics is recommended for RA patients refractory to MTX, particularly younger patients who need a high quality of daily life with less joint destruction and physical dysfunction. Although RA is one of the systemic autoimmune diseases that can often occur in women of reproductive age, the evidence of successful treatment of patients who are pregnant or planning for pregnancy is limited due to a lack of prospective case-control studies. Objectives Use of Tocilizumab (TCZ), such as interleukin-6 inhibitors, is recommended for patients who can not use the MTX. A strategy that includes RA treatment, a safe pregnancy and a healthy fetus is clearly needed. Most cases of TCZ prescribed to pregnant RA patients were found to produce satisfactory outcomes, but further information on the association between TCZ and pregnancy is lacking. The aim of this retrospective study is to investigate the details of TCZ use in pregnant RA patients, from planning the pregnancy to actual delivery, and to examine the pregnancy outcomes of RA patients treated before or at conception with TCZ. Methods In 1356 cases of RA patients registered in Nagoya medical center, patients using biologics were 532 cases. Of which, patients treated with TCZ were 111 examples. 7 pregnancies were identified and observed from the 111 patients treated with TCZ Results 7 pregnancy of patients in the TCZ use six cases (one case of preterm low birth weight infants), abortion was 1 cases. They age were from 28 years to 42 years. Five cases was (washout period was from 2 months to 11 months) pregnant after Biologics free. One case was continued TCZ during pregnancy. Medical condition had worsened during pregnancy are three cases, there were four cases of what deterioration was observed after delivery. Conclusions TCZ is a pregnancy risk category C drug, according to the US FDA. The category C risk summary states the following: "Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks". Japanese drug information states that TCZ should be administered to pregnant patients only if the benefits outweigh the risks; therefore, TCZ use in pregnant RA patients is not necessarily prohibited. Still, some review papers have concluded that TCZ should be discontinued three months before conception reported that IL-6 was the one of the causes of preterm premature rupture of membranes (PPROM) and that TCZ inhibited IL-6-mediated matrix metalloproteinase-2 and -9 secretion from human amnion cells. Although their study showed that TCZ might be useful for treating PPROM, the data on TCZ and pregnancy in humans were too limited to make conclusions on safety or suggestions on prescriptions. References Østensen M, et al.Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011; 23: 293-8. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.1417 |
Author | Kaneko, A. Takahashi, N. Ishikawa, H. Sato, T. Osawa, Y. Hattori, Y. Kida, D. |
Author_xml | – sequence: 1 givenname: H. surname: Ishikawa fullname: Ishikawa, H. organization: Orthopaedic Surgery and Rheumatology, Nagoya medical center – sequence: 2 givenname: A. surname: Kaneko fullname: Kaneko, A. organization: Orthopaedic Surgery and Rheumatology, Nagoya medical center – sequence: 3 givenname: Y. surname: Hattori fullname: Hattori, Y. organization: Orthopaedic Surgery and Rheumatology, Nagoya medical center – sequence: 4 givenname: N. surname: Takahashi fullname: Takahashi, N. organization: Orthopaedic Surgery and Rheumatology, Nagoya University, Nagoya, Japan – sequence: 5 givenname: D. surname: Kida fullname: Kida, D. organization: Orthopaedic Surgery and Rheumatology, Nagoya medical center – sequence: 6 givenname: T. surname: Sato fullname: Sato, T. organization: Orthopaedic Surgery and Rheumatology, Nagoya medical center – sequence: 7 givenname: Y. surname: Osawa fullname: Osawa, Y. organization: Orthopaedic Surgery, Japanese Red Cross Nagoya Daiichi Hospital |
BookMark | eNqVkEFLwzAYhoNMcJv-h8DOnUmTNi2exnA6GGyM6jWkSeoy1nQmKTJPXvyj_hJb58Grp4_v43nfD54RGNjGagAmGE0xJumtsNbtdFsr46MYYRrp9iDcFFPMLsAQ0zTrzikagCFCiEQ0T9kVGHm_71aU4WwInhfbJSIx-vr43Dj9YoWVJ7hug2xq7aGxcNv3i9AYBWcu7JwJxsONCEbb4GHhtAhawTcTdrBopDmY9w4vr8FlJQ5e3_zOMXha3Bfzx2i1fljOZ6uoxFlCIhXnKleUKiSIVCVlSiKFVJzqjCSV1JVmFdVSCFlJkeSslFWOSlFiFqNExhkZg8m59-ia11b7wPdN62z3kmPGWM4oiUlH3Z0p6Rrvna740ZlauBPHiPci-R-RvBfJf0TyXmSXTs_pst7_K_gN_DmDYg |
CODEN | ARDIAO |
CitedBy_id | crossref_primary_10_5499_wjr_v5_i2_82 |
ContentType | Journal Article |
Copyright | 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions Copyright: 2014 (c) 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
Copyright_xml | – notice: 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: Copyright: 2014 (c) 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
DBID | AAYXX CITATION 3V. 7X7 7XB 88E 88I 8AF 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9- K9. LK8 M0R M0S M1P M2P M7P PQEST PQQKQ PQUKI PRINS Q9U |
DOI | 10.1136/annrheumdis-2014-eular.1417 |
DatabaseName | CrossRef ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection BMJ Journals ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Biological Sciences Consumer Health Database Health & Medical Collection (Alumni Edition) Medical Database Science Database Biological Science Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic |
DatabaseTitle | CrossRef ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest Central Student |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-2060 |
EndPage | 502 |
ExternalDocumentID | 4008702141 10_1136_annrheumdis_2014_eular_1417 |
GroupedDBID | --- .55 .GJ .VT 0R~ 23M 2WC 39C 3O- 3V. 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOFX ACPRK ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FRP FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IGG IHR INH INR IOF J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PQQKQ PROAC PSQYO Q2X R53 RHF RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP AAYXX CITATION 7XB 8FK K9. PQEST PQUKI PRINS Q9U |
ID | FETCH-LOGICAL-b1853-d29d9d44d0a3cdb47dc0d0d26e835fcefe7f4ecaacfca597bcf90bab17205c283 |
IEDL.DBID | BENPR |
ISSN | 0003-4967 |
IngestDate | Fri Sep 13 05:11:03 EDT 2024 Fri Aug 23 02:18:43 EDT 2024 Wed Aug 21 03:27:34 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1853-d29d9d44d0a3cdb47dc0d0d26e835fcefe7f4ecaacfca597bcf90bab17205c283 |
PQID | 1777974323 |
PQPubID | 2041045 |
PageCount | 2 |
ParticipantIDs | proquest_journals_1777974323 crossref_primary_10_1136_annrheumdis_2014_eular_1417 bmj_primary_10_1136_annrheumdis_2014_eular_1417 |
PublicationCentury | 2000 |
PublicationDate | 20140600 2014-06-00 20140601 |
PublicationDateYYYYMMDD | 2014-06-01 |
PublicationDate_xml | – month: 06 year: 2014 text: 20140600 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Annals of the rheumatic diseases |
PublicationYear | 2014 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
SSID | ssj0000818 |
Score | 2.149401 |
Snippet | Background Biological agents (“biologics”), such as anti-tumor necrosis factor (TNF) agents and interleukin-6 (IL-6) inhibitors, have been widely used in... Background Biological agents ("biologics"), such as anti-tumor necrosis factor (TNF) agents and interleukin-6 (IL-6) inhibitors, have been widely used in... |
SourceID | proquest crossref bmj |
SourceType | Aggregation Database Publisher |
StartPage | 501 |
Title | FRI0320 Pregnancy Outcomes in Rheumatoid Arthritis Patients Treated with Tocilizumab |
URI | http://dx.doi.org/10.1136/annrheumdis-2014-eular.1417 https://www.proquest.com/docview/1777974323/abstract/ |
Volume | 73 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEB5sheJFfGK1yoJel6bJJpucRKWlCmopLfQW9hVb0Vr7OOivdyZNKF4Er8luSL7dzH4zszsfwJWi7TRhYHnkK8mFzTKupdU8UrELA4PuWEaHkx-fou5QPIzC0RZ0y7MwtK2ytIm5obYfhmLkzZaUErlv4AdNpSkKYJbN69knJ_0oyrMWYhoV2PZbghK227ftp15_Y5XjVlyq54kkkjW4LBRNSPBlPnardztZ4KRpCe5oByjaEFIxq-j3199r1m-Tna9DnT3YLQgku1mP-D5suekB1B6LFPkhDDr9e5IrZ725e6FqGl_sebXEb3QLNpmyPr0COtoTS48Y5yWNWG9dXHXBBkQhnWUUnWUDHLe3yTc210cw7LQHd11eSCdwTQswt35iEyuE9VRgrBbSGs961o8cMq7MuMzJTDijlMmMQp9CmyzxtNJIZ7zQIOU4hur0Y-pOgCls6mm8FCkjwjhRcYysSwujksQ4K-vQRIjS2bo4Rpo7FUF-0LkENSVQ0xzUlECtgyjh_F-3Rgl9Wvxoi3QzLU7_vn0GO_nY5gGUBlSX85U7Rz6x1BdQkSN5UUyYHw-izkE |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,33779,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEF5sBfUiPvFRdUGvS9Nmk01OImKpj9ZSIvQW9hUb0apNe9Bf78w2QXoRvCa7Ifl2M_vN7Ox8hFxITKcJfMPCthSMmyxjShjFQhnZwNfgjmV4OLnXD7tP_G4UjMqAW1GmVVY20Rlq864xRt5sCSGA-_pt__Ljk6FqFO6ulhIaNbLKfZ9jSp8YiV9LHLWiSjGPx6FYI-eligmKvEzHdv5m8gImSoszi1mfYDdQuaym3l6W16llM-3Wns4W2SxJI71ajPI2WbGTHbLWK7fFd0nSGd6iRDkdTO0zVtD4oo_zGXyXLWg-oUN8BXCuc4OPGLsyRnSwKKha0ARpozUUI7I0gbF6zb-hudojT52b5LrLSrkEpnDRZaYdm9hwbjzpa6O4MNoznmmHFlhWpm1mRcatllJnWoIfoXQWe0oqoDBeoIFm7JP65H1iDwiV0NRTcCmUmgdRLKMImJbiWsaxtkYckiZAlH4sCmKkzpHw3eHmCtQUQU0dqCmCekh4Bef_ujUq6NPy5yrS36lw9PftM7LeTXoP6cNt__6YbLhxdgGUBqnPpnN7Anxipk7dpPkBpfXLJw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEF58QPEiPvHtgl6Xps0mm5xE1FJftZQWegv71IpWbdqD_npnthvEi-A1L5JvJzPf7M7OR8ipxHKaJDYsbUrBuHGOKWEUS2Vmk1hDOuZwc_J9J20P-M0wGYb6pzKUVVY-0Ttq86ZxjrzeEEIA942bcd2FsojuZevs_YOhghSutAY5jUWyDFEyQjUDMRQ_XjlrZJV6Hs9TUSMnQdEEBV8mT3b2akYlGE2DM4sVoOBDUMVsUb0-_45Zv122j0OtNbIaCCQ9n4_4Olmw4w1Suw9L5Juk3-pdo1w57U7sI3bT-KQPsyl8oy3paEx7-AqQaI8MPuLJtzSi3Xlz1ZL2kUJaQ3F2lvZh3F5GX3C52iKD1lX_os2CdAJTGICZaeYmN5ybSMbaKC6MjkxkmqkFxuW0dVY4brWU2mkJOYXSLo-UVEBnokQD5dgmS-O3sd0hVMKlkYJDqdQ8yXKZZcC6FNcyz7U1YpfUAaLifd4co_BJRew3OlegFghq4UEtENRdwis4_3fbQQV9EX60svgxi72_Tx-TGthLcXfdud0nK36Y_VzKAVmaTmb2EKjFVB15m_kG1bXPUw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FRI0320%E2%80%85Pregnancy+Outcomes+in+Rheumatoid+Arthritis+Patients+Treated+with+Tocilizumab&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Ishikawa%2C+H.&rft.au=Kaneko%2C+A.&rft.au=Hattori%2C+Y.&rft.au=Takahashi%2C+N.&rft.date=2014-06-01&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=73&rft.issue=Suppl+2&rft.spage=501&rft_id=info:doi/10.1136%2Fannrheumdis-2014-eular.1417&rft.externalDBID=ttp%3A%2F%2Fard.bmj.com%2Fcontent%2F73%2FSuppl_2%2F501.2.full.pdf |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |